1333 related articles for article (PubMed ID: 22734080)
1. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 18F-FDG PET/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis.
Cheng X; Li Y; Xu Z; Bao L; Li D; Wang J
Acta Radiol; 2011 Sep; 52(7):779-87. PubMed ID: 21712464
[TBL] [Abstract][Full Text] [Related]
3. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
Mghanga FP; Lan X; Bakari KH; Li C; Zhang Y
Clin Breast Cancer; 2013 Aug; 13(4):271-9. PubMed ID: 23714689
[TBL] [Abstract][Full Text] [Related]
4. Dual time point 18FDG-PET/CT versus single time point 18FDG-PET/CT for the differential diagnosis of pulmonary nodules: a meta-analysis.
Zhang L; Wang Y; Lei J; Tian J; Zhai Y
Acta Radiol; 2013 Sep; 54(7):770-7. PubMed ID: 23528566
[TBL] [Abstract][Full Text] [Related]
5. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
[TBL] [Abstract][Full Text] [Related]
6. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
Lin CY; Lin CL; Kao CH
Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
[TBL] [Abstract][Full Text] [Related]
7. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Liu Q; Wang C; Li P; Liu J; Huang G; Song S
Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis.
Zhao JY; Ma XL; Li YY; Zhang BL; Li MM; Ma XL; Liu L
Asian Pac J Cancer Prev; 2014; 15(8):3525-31. PubMed ID: 24870751
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis.
Treglia G; Sadeghi R; Annunziata S; Lococo F; Cafarotti S; Bertagna F; Prior JO; Ceriani L; Giovanella L
Acad Radiol; 2014 Jan; 21(1):11-20. PubMed ID: 24331260
[TBL] [Abstract][Full Text] [Related]
13. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
Li H; Yao L; Jin P; Hu L; Li X; Guo T; Yang K
Breast; 2018 Aug; 40():106-115. PubMed ID: 29758503
[TBL] [Abstract][Full Text] [Related]
14. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment.
Zhang S; Han D; Tan X; Feng J; Guo Y; Ding Y
Int J Clin Pract; 2012 Feb; 66(2):185-98. PubMed ID: 22257044
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of 18 F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer.
Ko WS; Kim SJ
Clin Nucl Med; 2023 Jul; 48(7):574-580. PubMed ID: 36976654
[TBL] [Abstract][Full Text] [Related]
18. Is diffusion-weighted MRI superior to FDG-PET or FDG-PET/CT in evaluating and predicting pathological response to preoperative neoadjuvant therapy in patients with rectal cancer?
Li YL; Wu LM; Chen XX; Delproposto Z; Hu JN; Xu JR
J Dig Dis; 2014 Oct; 15(10):525-37. PubMed ID: 25060294
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies.
Yu T; Meng N; Chi D; Zhao Y; Wang K; Luo Y
Cell Biochem Biophys; 2015 Jun; 72(2):443-51. PubMed ID: 25737131
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with Merkel cell carcinoma: a systematic review and meta-analysis.
Treglia G; Kakhki VR; Giovanella L; Sadeghi R
Am J Clin Dermatol; 2013 Dec; 14(6):437-47. PubMed ID: 23959776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
